Skip to main content
. 2023 May 12;23:249. doi: 10.1186/s12872-023-03269-w

Table 2.

Baseline patient characteristics in sham arm of included randomized clinical trials

SYMPLICITY HTN-3 Desch et al. ReSet RADIANCE-HTN SOLO SPYRAL HTN-OFF MED Pivotal SPYRAL HTN-ON MED REDUCE HTN: REINFORCE REQUIRE RADIANCE-HTN TRIO
Number of patients 171 36 33 72 165 42 17 67 67
Age - n ± SD 56.2 ± 11.2 57.4 ± 8.6 57.1 ± 6.6 53.8 ± 10 52.6 ± 10.4 53 ± 10.7 58.2 ± 9.8 55.6 ± 12.1 52.8 ± 9.1
Gender (male) - n (%) 110 (64.3) 25 (69) (73) 39 (54) 113 (68) 34 (81) 13 (76) 53 (79.1) 53 (79)
Race - n (%)
white 119 (69.6) 36 (100) (97) 52 (72) 50 (30) 15 (36) 14 (82) NR 50 (75)
black 50 (29.2) 0 NR 13 (18) 31 (19) 5 (12) 3 (18) NR 12 (19)
other 2 (1.2) 0 NR 7 (10) 5 (3) Δ 1 (2) ¥ 1 (6) NR 3 (4.5) ‡
Comorbidities - n (%)
Chronic Kidney Disease - GFR < 60 17 (9.9) NR * (18) 3 (4) NR NR NR ** 18 (26.9) 7 (11)
Diabetes Mellitus 2 70 (40.9) 13 (36) (31) 5 (7) 9 (5) 8 (19) 2 (12) 20 (29.9) 17 (25)
Obstructive Sleep Apnea 54 (31.6) NR (12) 8 (11) 12 (7) 10 (24) 1 (6) 8 (11.9) 11 (16)
Peripheral Artery Disease 5 (2.9) 2 (6) NR NR 0 0 NR 2 (3) NR
Coronary Artery Disease 43 (25.1) 17 (47) (15) NR 8 (5) 1 (2) 3 (18) 9 (13.4) NR
Smokers - n (%) 21 (12.3) 4 (11) (15) NR 27 (16) 11 (26) 2 (12) NR NR
Hyperlipidemia - n (%) 111 (64.9) NR NR NR NR NR 4 (24) 40 (59.7) NR
BMI (kg/m 2 ) - n ± SD 33.9 ± 6.4 31.2 ± 4.6 28.8 ± 3.9 29.0 ± 5.0 30.9 ± 5.5 32.5 ± 4.6 NR 28.4 ± 4.5 32.6 ± 5.4
Mean number of antihypertensive agents - n ± SD 5.2 ± 1.4 4.3 ± 1.3 4.2 ± 1.1 0 (OFF MED) 0 (OFF MED) 2.3 ± 0.8 0 (OFF MED) NR NR

Values are n ± SD or n (%). SD – Standard Deviation; NR – not reported; BMI – Body Mass Index; GFR – Glomerular Filtration Rate

Δ Not reported for 79 (48) patients; ¥ Not reported for 20 (48) patients; ‡ Not reported for 2 (3) patients; * Only reported mean GFR − 84 ± 20 ml/min/1.73 m2; ** Only reported mean GFR − 86.2 ± 16.2 ml/min/1.73 m2